Masimo (NASDAQ: MASI) will release first quarter 2025 financial results for the period ended March 29, 2025, after the market closes on Tuesday, May 6, 2025. The conference call to review the results ...

The complete response letter did not identify any issues with the safety or efficacy of Eylea HD, Regeneron officials said.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter ...

EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

Regeneron (REGN) announces FDA review of sBLA for Eylea HD to treat macular edema and expand dosing. Read more here.

While one netizen (@superklimber) defended Justin Bieber by saying that the singer most likely didn't mean to call Stevie Wonder blind as an insult. Other netizens pointed out that the musician was ...

Vantage Biosciences has successfully dosed the first patient in its phase 2 clinical study evaluating VX-01, an oral therapy for the treatment of nonproliferative diabetic retinopathy (NPDR).

The review article examines the relationship between anemia and retinopathy of prematurity, focusing on iron deficiency and underlying molecular mechanisms Anemia is a common condition in premature ...

It is currently scaling an AI solution that it began piloting in 2022: Digital Diagnostics’ AI system that autonomously diagnoses diabetic retinopathy. The system, called the LumineticsCore ...

Bevacizumab may be preferable to ranibizumab in the treatment of retinopathy of prematurity in as far as it is associated with a lower risk of retreatment. Patients with retinopathy of prematurity ...